Blocking Type-1 Hypersensitivity
Using Monoclonal Antibodies Against Human IgE
A new approach to treating and preventing Type-I hypersensitivity
involves giving the person with allergies injections of monoclonal antibodies
that have been made against the Fc portion of human IgE. This, in turn, blocks
the attachment of the IgE to the Fc receptors on mast cells and basophils
and the subsequent release of histamine and other inflammatory mediators by those cells upon subsequent exposure to allergen.